Enrico Ferro: Comparative Study Raises Questions on PFA Safety in AF at EHRA 2026
Enrico Ferro, Electrophysiology Fellow at Beth Israel Lahey Health, Clinical Investigator at Richard A. and Susan F. Smith Center for Outcomes Research, shared on LinkedIn:
”It was great to present our latest study at EHRA 2026 in Paris for the Young Investigator Award.
We ran one of the largest comparative safety analyses of PFA vs radiofrequency ablation for AF, performed at Beth Israel Deaconess Medical Center (large volume, tertiary care center, >1,500 PVI per year).
- Large study cohort of ~4,000 patients (2,000 PFA vs 2,000 RF);
- 2 strokes (0.1%) in the RF arm (2022-2024);
- 10 strokes (0.5%) in the PF arm (2024-2026);
- Strokes were not clustered at the time of PF adoption. They were evenly distributed throughout the study period;
- There was no correlation between strokes and physician experience or procedural volume – there was no learning curve effect;
- We report stroke rates with other commercial PFA platforms beyond Farapulse, with a sizable amount of Sphere 9 cases (~500 pts);
- These data show a uniform stroke rate across PFA platforms (~0.4%) and preliminarily suggest a possible PFA class effect.
- Of note, posterior wall isolation was performed in 60% of PF cases, vs only 30% of RF cases. As expected, there is more extensive ablation with PFA, and we need to accrue more stroke events to power a mediator model and understand if more extensive ablation may explain the higher stroke rate.
In summary, our study found that the modern ‘PFA strategy’ seems associated with a significantly higher stroke risk, compared to the ‘RF strategy’.
As we accrue events and increase power, we will re-run the model to understand which specific element(s) of the PFA strategy may explain the high observed stroke rate.
Stay tuned!”

Stay updated with Hemostasis Today.
-
Sep 5, 2026, 16:28Jon Douglas: Imperial College London Review Maps Key Pathways in Autoimmune Thrombosis
-
Sep 5, 2026, 16:21Kelly Anderson: Bilateral Foot Pain and Purple Toes – Spotting Vascular Complications in Polycythemia Vera
-
Sep 5, 2026, 16:16Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis
-
Sep 5, 2026, 16:08Indre Ceponiene: Major Gaps in Secondary Cardiovascular Prevention Across Europe
-
Sep 5, 2026, 16:03W. Alberto Sifuentes Giraldo: Why Obstetric Cases Are Missed Under 2023 ACR/EULAR APS Criteria
-
Sep 5, 2026, 15:58Srikanth Nalla: A Case of Saddle Pulmonary Embolism
-
Sep 5, 2026, 15:55COPD-specific Pulmonary Embolism Diagnostic Strategy – Thrombosis and Haemostasis
-
Sep 5, 2026, 15:41Sam Tsimikas on Lp(a) HORIZON Topline Results – What Missed Endpoints Mean for Cardiovascular Risk
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?